Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

April 28, 2020

New York Stock Exchange US Health Care Pharmaceuticals earnings 76 min

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Thanks, Jerome, and good morning. I want to welcome everyone to the conference call for Merck's first quarter of 2020. On the line with me today are Ken Frazier, who serves as our Chairman and Chief Executive Officer; Rob Davis, our Chief Financial Officer; Dr. Roger Perlmutter, who leads Merck Research Labs as President; Frank Clyburn, our Chief Commercial Officer; and Mike Nally, our Chief Marketing Officer. Before handing things over to Ken, there are a few points I want to make. In our GAAP results, you'll notice certain items, including charges tied to acquisitions, expenses for restructuring, and some other things. Please be aware that these have been left out of our non-GAAP results, and a reconciliation is available in our press release. Our press release also includes a table designed to give you a clearer picture of how the business units and products performed in sales during the quarter. Let me also remind everyone that a number of the remarks we're making on this call could be viewed as forward-looking statements under the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These remarks reflect what Merck's management currently believes, and they carry substantial risks and uncertainties. Should our underlying assumptions turn out to be wrong, or should uncertainties come to pass, actual results could end up differing materially from what those forward-looking statements describe. Our SEC filings, including Item 1A in the 2018 10-K, lay out specific risk factors and cautionary statements that might lead the company's actual results to differ materially from any projections in the forward-looking statements we're making this morning. Merck has no obligation to publicly update any forward-looking statements. Our SEC filings, the earnings release issued today, and an investor presentation containing some highlights of our results can all be found on merck.com. With that said, I'll hand the call over to Ken.

Ken Frazier

executive
#2

Thanks, Peter. Good morning, everyone, and I appreciate you being on the call today. During this difficult and unprecedented period, our results for the first quarter show robust demand for our lineup of innovative products, along with ongoing execution in commercial and clinical areas and the commitment and toughness of our workforce globally. Our business fundamentals continue to be solid. The worldwide COVID-19 pandemic presents remarkable difficulties for everyone, including grave risks to human health, companies, and economies across the globe. Clearly, both our sector and our organization possess a distinctive capacity and obligation to assist the world in tackling this worldwide pandemic through collaborative work aimed at providing remedies for coronavirus infection, while simultaneously sustaining supplies of medically vital products for those in need. In the middle of this emergency, all of us at Merck are concentrating on safeguarding the well-being and safety of our staff and their loved ones, while making sure our critical medicines and vaccines keep getting to the patients we serve. Crucially, most of Merck's manufacturing facilities and clinical supply locations are still operating at full capacity. And we have observed minimal disruption to how our medicines, vaccines, and Animal Health products are produced, supplied, or distributed. Across numerous markets globally, such as the U.S., although our offices and labs are still open, our team members are largely working from their homes; and for patients who are presently taking part in our clinical trials, we are doing everything possible to guarantee that those in impacted regions can keep receiving their treatments and get suitable care and monitoring. Circumstances are changing and in flux. Yet when situations permit, we are bringing patients into existing studies, and we are launching new ones. Naturally, there is significant curiosity about our scientific efforts regarding COVID-19. Roger Perlmutter will discuss the full scope of what we are doing in greater depth. However, I want to note that we possess extensive scientific background and proficiency in antivirals as well as vaccines; and our research teams are actively involved in initiatives to fight COVID-19. We have groups of scientists examining COVID-19 directly, and evaluating antiviral and vaccine possibilities for their capacity to affect the illness. Furthermore, we have been collaborating broadly with the wider scientific community to evaluate various assays and have been interacting with many research bodies on joint endeavors; we understand from our history with viral outbreaks such as HIV and Ebola, that scientific partnerships are crucial for creating medicines and vaccines during a worldwide public health crisis like the current one; we also recognize that the journey to a novel medicine or vaccine is seldom brief, nor is it simple. Yet we remain hopeful that our industry's endeavors will produce new instruments to fight this coronavirus. And Merck is dedicated to contributing its share in addressing this worldwide pandemic for the patients who rely on our medicines and vaccines, the global community, and those directly affected by COVID-19. The basic demand for our innovative product portfolio continues to be robust and our business stays fundamentally healthy. Yet the pandemic is making it harder for patients to get to hospitals and doctors' offices, especially for a lot of our offerings that need a physician to administer them; on top of that, social distancing steps are affecting how customers can reach and how much they want our Animal Health products. In a moment, Rob and Frank will cover the short-term effects on our business; over a longer horizon, though, we stay confident about our prospects for robust growth once individuals adapt and discover approaches to meet health and healthcare needs in a world after COVID-19. Crucially, our financial strength and solid balance sheet let us keep pursuing our capital allocation priorities, among them putting money into R&D and into our growth drivers, funding expansion of manufacturing capacity, paying our dividends, and pressing ahead with our hunt for value enhancing business development, which is still a top priority. We are likewise still fully committed to a spin-off transaction, and we think we are on track to finish in the first half of 2021. During the quarter we completed a number of important milestones, such as naming the new company Organon & Co. Inc, a name that carries strong brand equity and builds trust among healthcare professionals because of its dedication and innovation in Women's Health. We have also named several members of the Organon leadership team; we continue to believe that two more focused companies will let us reach more patients, drive stronger growth, and unlock longer term value for shareholders. In closing, we recognize now more than ever how important our investment in R&D is, and how valuable our science-based approach is; we stay dedicated to our mission to save and improve lives through the discovery of innovative new medicines and vaccines to treat and protect patients in the midst of the pandemic and in the future. With that, I'll now hand it over to Rob Davis to review the details of our performance and outlook.

Rob Davis

executive
#3

Thanks, Ken, and good morning to all of you. As Ken mentioned, even though these are difficult times, our Q1 performance shows the solid fundamentals underpinning our business, along with effective planning and execution that has kept our medicines and vaccines flowing without interruption to the patients who depend on us. Our confidence in long-term growth remains intact, fueled by robust underlying demand for what we make. That said, it's clear COVID-19 will weigh on our near-term numbers, largely because of obstacles patients face in gaining access. Against that backdrop, our robust financial standing and conservatively structured balance sheet let us preserve solid liquidity and excellent access to capital markets, and our priorities for allocating capital are essentially unaffected. Moving now to Q1 results. Company-wide revenues came in at $12.1 billion, up 11% versus a year ago, or 13% once you strip out the drag from foreign exchange. Growth this quarter came from both Human Health and Animal Health. COVID-19's effect on our business during Q1 was immaterial, with pushes and pulls balancing out across divisions and regions. Everything further I say about sales will be on an ex-exchange basis. Human Health revenues rose 12%, powered by leading products in oncology, vaccines and hospital. Within oncology, KEYTRUDA sales climbed 46% compared with a year earlier, hitting $3.3 billion. Stateside growth came from every key tumor type; and we keep reinforcing our overall leadership in the I/O market, spanning indications in lung, bladder and head and neck cancers. Our launches in renal cell carcinoma and endometrial and first-line head and neck cancers keep building momentum; and we're excited about what lies ahead for our filing for a six week dosing regimen across all indications, which the FDA is reviewing right now. Beyond the United States, lung cancer indications keep fueling KEYTRUDA growth. In the EU, uptake of KEYNOTE-189 with secured reimbursement across every major market continues to power growth, and early uptake in the adjuvant melanoma, head and neck and renal cell carcinoma launches is encouraging. In Japan, KEYTRUDA grew on the back of new launches and ongoing strength in lung, even with the huge seller price adjustment taking effect in February. Our oncology portfolio keeps gaining from Lynparza and Lenvima, with Lenvima still leading the PARP class in the United States at over 60% share, while Lenvima holds market leadership in first-line hepatocellular carcinoma and gains from the launch in combination with KEYTRUDA and in endometrial carcinoma. Moving on to vaccines. GARDASIL's growth mirrors sustained positive underlying demand worldwide plus the timing of shipments in China, which added roughly $120 million in growth for the quarter, and the timing of public sector purchases in the U.S., which lifted revenue by approximately $70 million. PNEUMOVAX played a role in this quarter's growth as well, partly because demand rose alongside greater interest in pneumococcal vaccination stemming from the COVID-19 pandemic across the United States and Europe. In our hospital business, we saw gains from BRIDION recycling performing strongly in every major region, along with PREVYMIS, which reflected demand plus the advantages of launches around the world. Revenue for Animal Health rose 21% in the quarter, reaching $1.2 billion. Livestock was up 24%, mainly thanks to the Antelliq acquisition's contribution and COVID-19 related buy-in. Companion Animal climbed 17%, propelled by demand for BRAVECTO and the COVID-19 related buy-in as well. Now moving to the remaining parts of our P&L, everything I say will be on a non-GAAP basis. Gross margin came in at 75.5% for the quarter, which is 40 basis points lower than a year earlier. Operating expenses totaled $4.4 billion, essentially unchanged from the prior year. SG&A declined 7%, pushed down by reduced promotion and selling costs tied in part to COVID-19, whereas R&D rose 10%, reflecting greater clinical development and research expenses along with higher licensing costs. All told, COVID-19 reduced our spending by $100 million, which helped our operating expenses, mostly from lower promotional and selling costs and postponed spending on clinical trials. The rise in other expense compared with last year came from higher net interest expense caused by smaller cash balances, partly offset by net gains on our security holdings, chiefly our investment in Moderna. Our effective tax rate for the quarter stood at 17%. Adding it all up, we earned $1.50 per share, which is 26% higher excluding exchange. To sum up, underlying demand for our products during the first quarter, even once timing and COVID-19 effects are factored out, produced very strong growth and shows the ongoing underlying strength and operational momentum within our business. As the year progresses and we finally leave COVID-19's impact behind, that demand will serve as the foundation for what we expect will be strong and sustained growth going forward; now turning to our outlook for the rest of the year. Entering the second quarter, patient visits are declining because of reduced access to hospitals and other healthcare providers, along with social distancing recommendations. I'd like to hand the call over to Frank for more color on the dynamics we're observing.

Frank Clyburn

executive
#4

Rob, thank you, and good morning to all of you. Ken and Rob have already explained that the damage the pandemic continues to inflict on our operations stems primarily from fewer interactions between healthcare providers and patients, since hospitals are shifting resources to COVID-19 while patients steer clear of medical facilities and put off preventive care. To grasp what this means for Merck, you need to appreciate that physician-administered products carry a great deal of weight in our portfolio; in truth, about two-thirds of Human Health revenue worldwide comes from products a doctor administers. Going one step further, revised guidance and recommendations have arrived from the CDC along with multiple professional associations, reinforcing social distancing through postponed wellness visits and delayed treatment. Consider, for instance, that following advice from the American Academy of Pediatrics and CDC, the majority of pediatricians have deferred routine immunization for every child, with the exception of those younger than 24 months in the United States. Meanwhile, in the United States, visits to physician offices throughout many branches of medicine presently sit roughly 70% below where they stood before COVID-19. These measures have produced consequences for our vaccine portfolio, among them GARDASIL, PNEUMOVAX and our pediatric vaccines, and for our Women's Health offerings, covering both fertility medicines and IMPLANON/NEXPLANON, a physician-administered implantable. Non-urgent elective procedures have likewise been delayed or called off across most major markets as a way to curb transmission and let hospitals put COVID-19 patients first. Numerous sources describe present drops exceeding 70% in elective procedures, with urgent procedure volumes likewise suffering, albeit far less severely. Such decreases hit a product such as BRIDION, which finds use throughout many surgical settings. Even oncologists are postponing appointments and procedures, prioritizing patients by severity and the pressing requirements of distinct tumor types, which stretches dosing schedules for current patients and pushes back when newly diagnosed patients begin therapy. Yet, as Rob will explain shortly, drawing on our overarching assumption regarding when a more normal environment returns, together with what we witnessed in China — a market hit sooner by the pandemic yet now bouncing back — we anticipate the heaviest blow landing in the second quarter. Above all, we hold that underlying demand for our products stays robust, given the considerable medical advantages they deliver to patients. Once the pandemic's peak has passed, we expect providers and patients alike to act swiftly in finding safe ways to deliver and obtain treatment. And when a more normal setting for patient access is restored, we believe our portfolio will be — will once more be positioned well to deliver strong long-term growth. Having said that, I hand things back to Rob.

Rob Davis

executive
#5

Appreciate that, Ken. Moving on to guidance now — we're anticipating lower volumes because of the diminished access and social distancing effects Frank walked through, especially during the second quarter, which we're treating as the peak of the virus across the United States and Europe; we anticipate that this dynamic will start to fade as hospitals return to normal operations during the third quarter and as social distancing restrictions are gradually removed in various geographies, at which point we'd anticipate a stepwise return toward more typical volume levels, free of access constraints. Although we do anticipate reaching normal pre-COVID-19 volumes by the start of the fourth quarter, a substantial share of the Q2 impact will extend into the full year. Within Animal Health, we anticipate a longer recovery period, because of softer demand for milk and protein stemming from restaurant and school closures, fewer veterinary visits, and the effects of lower employment and incomes. Naturally, our actual results might differ depending on how the illness spreads and how individual countries react. Our current expectation is revenues between $46.1 billion and $48.1 billion, representing a $2.5 billion reduction from our prior midpoint; that gap consists of about $2.1 billion of adverse COVID-19 effects on an ex-exchange basis, split into roughly $1.7 billion from Human Health plus $400 million in Animal Health; we're also now factoring in an unfavorable foreign exchange effect of approximately $750 million, or 2.5 percentage points at mid-April rates. Lastly, Human Health operational momentum of about $300 million partly offsets the adverse COVID-19 and FX effects. Gross margin is now projected at approximately 75%. Operating expenses should decrease at a low-single-digit rate, primarily from reduced SG&A. Our revised assumption accounts for smaller promotional and selling costs along with lower clinical trial expenses. For the full year, we now project a tax rate between 17% and 18%; other expense remains expected at approximately $200 million. We still anticipate 2.54 billion shares outstanding. In light of present conditions and from an abundance of caution, we've temporarily halted our share repurchase program, which will help us safeguard a strong financial position so we can pursue our capital allocation priorities of investing in the business and continuing business development. All told, we now project non-GAAP EPS in the range of $5.17 to $5.37, a $0.43 decline from our prior midpoint; this range incorporates an adverse foreign currency effect of about 3.5 percentage points, equivalent to an FX headwind of approximately $0.11 relative to our earlier assumptions. Crucially, the company's financial strength and conservatively positioned balance sheet let us carry out our capital allocation priorities, which stay the same despite today's difficult conditions. At the close of the quarter, our cash and marketable securities totaled $8 billion, and we kept solid entry to commercial paper markets; on top of that, cash collections are proceeding just as anticipated, without any meaningful interruption stemming from COVID-19's effects so far. Let me remind you that investing in our current R&D programs comes first, along with backing new efforts focused on COVID-19. This pandemic highlights, now more than ever, how dedicated we are to R&D. We'll keep putting money into expanding manufacturing capacity, and paying our dividend stays a firm commitment. Beyond that, as Ken mentioned, business development is still a priority, and we'll keep seeking the finest external sources of science to strengthen our pipeline. We'll evaluate conditions continuously and think about restarting the buyback program when it makes sense; to sum up, results from our first quarter show the robust demand for our innovative portfolio and the fundamental strength beneath our business. Though the pandemic will affect us near-term, our financial position is sound enough to ride out this storm and sustain the investments we're making throughout our business to fuel growth and, crucially, to deliver more innovations to the patients we serve. We're also still confident about underlying demand for our products, given their competitive standing and the advantages they offer, and we fully anticipate growth returning once patient access gets back to normal. Consequently, our expectations haven't changed when it comes to our capacity to achieve sustainable long-term growth. We see all of this as continuing to generate substantial and lasting long-term value for our patients as well as our shareholders. With that, I'll hand the call over to Roger.

Roger Perlmutter

executive
#6

Thanks, Rob. My comments on the first quarter results will be split into three sections. To start, I'll cover where Merck Research Laboratories stands operationally right now, with a focus on clinical research and how we're engaging with regulatory agencies. Next, I'll call out several key results from the first quarter and sketch out some of our goals as the year moves along. Last, I'll speak directly about the steps we've taken, and those we intend to take, in order to help with the COVID-19 pandemic. Let me start with how we're operating. Early on, our global clinical operations team understood how significant the SARS-CoV-2 infections being reported in Wuhan, China were, and they made preparations in advance to handle what turned into the COVID-19 pandemic. Those preparations involved placing clinical supplies ahead of time, making our clinical supplies network stronger, establishing processes that allow virtual monitoring, and gradually building out processes for home delivery of investigational agents, which in certain instances included setting up alternative infusion sites. By operating virtually, the clinical operations team, along with data management and our quality organization, has managed to keep our overall clinical trial schedule on track; in certain jurisdictions we have lowered enrollment in some cases; however, we have not stopped enrollment and continue to start new clinical trials in most jurisdictions. For instance, during March our team handled 36 database logs and brought in over 700 new patients at our Europe, Middle East, Africa sites. Those figures offer considerable reassurance that our clinical programs continue to advance. In fact, while I can't forecast how the pandemic will unfold going forward, at this point our 2020 MRL objectives remain safe. All of this progress stems entirely from the remarkable efforts of teams throughout our organizations, which span five continents, and from a very wide array of government regulatory agencies that we work with. Now let me turn to significant research achievements. As mentioned before, the first quarter opened with FDA approval of KEYTRUDA as a monotherapy for treating certain patients who have high risk, non-muscle invasive bladder cancer — our 23rd indication for KEYTRUDA — and we keep producing important data about how KEYTRUDA can improve cancer therapy. A preliminary look at the pivotal Phase 3 KEYNOTE-355 trials showed that when KEYTRUDA was given alongside standard chemotherapy, progression-free survival got better compared with chemotherapy by itself as a first-line therapy for patients suffering from metastatic triple-negative breast cancer, where their tumors had PD-L1 expression with a combined proportion score of at least 10; this finding adds to what we learned from KEYNOTE-522, where giving KEYTRUDA plus chemotherapy as neoadjuvant treatment rather than chemotherapy alone boosts the pathologic complete response rate among patients having surgery for triple-negative breast cancer; we plan to lay out these findings thoroughly at a medical meeting in the near future; we also shared results from KEYNOTE-204 showing that KEYTRUDA used alone as monotherapy enhanced progression-free survival for adults with relapsed or refractory classical Hodgkin lymphoma when measured against brentuximab vedotin. Such data give strong backing to the indication we currently hold in classical Hodgkin lymphoma. And the trial is set to keep allowing assessment of the dual primary overall survival endpoint. In addition, over the quarter, we reported findings from KEYNOTE-177, a Phase 3 trial where KEYTRUDA as monotherapy bettered progression-free survival relative to standard chemotherapy as first-line therapy for patients with unresectable or metastatic colorectal cancer, whose tumors showed deficiency in mismatch DNA repair or signs of DNA microsatellite instability, what is known as the MSI high phenotype. The trial will go on, per usual practice, to allow assessment of an overall survival endpoint when the data reach maturity. Many will remember that back in 2017 we secured the very first approval for a tumor agnostic PD-1 directed therapy indication, after identifying, together with colleagues at Johns Hopkins University, MSI high status as a biomarker for tumor responsiveness. As the first quarter closed, we additionally obtained priority review from the FDA for what we see as a second possible tumor agnostic indication, using KEYTRUDA in certain patients whose tumors carry a high mutational burden, meaning greater than or equal to 10 mutations per megabase of DNA, no matter the tumor type. We are eager to share all this data at scientific meetings ahead and in peer reviewed journals. As I mentioned, we are likewise in conversations with regulatory agencies about this data. Lastly, we said last week that following talks with the FDA, we answered their earlier Complete Response Letter and resubmitted our application seeking approval for KEYTRUDA in a 400 milligram every six weeks dosage form across all indications in adults, drawing on both modeling information and new data coming out of KEYNOTE-555, which will be covered in part at the American Association for Cancer Research Meeting later today. We have also made meaningful strides in our partnership with AstraZeneca around Lynparza, our leading PARP inhibitor. Only a week ago, we shared fresh findings from a key secondary endpoint of the PROfound trial. Those findings demonstrate a statistically significant gain in overall survival among men who have metastatic castration-resistant prostate cancer and whose tumors carry mutations in BRCA1, BRCA2, or ATM — genes that matter for homologous recombination related DNA repair — after they received Lynparza rather than abiraterone or enzalutamide. This outcome offers one more illustration of how Lynparza helps patients whose tumors harbor defined DNA repair mutations. Let me remind everyone that primary data from the PROfound studies were presented by us at the European Society for Medical Oncology Meeting in October of 2019; the full details of the PROfound study — not the ones just announced — should appear in the top tier medical journal very soon, possibly this week. Regarding Lynparza, I should also point out that our PAOLA-1 study, a Phase 3 trial looking at Lynparza plus bevacizumab against bevacizumab by itself in first-line maintenance treatment for women with advanced overall — ovarian cancer, is being reviewed by the FDA, with a PDUFA date in the second quarter. I cannot finish our review of significant tumor therapy results without bringing up the approval two weeks ago of Koselugo, generically called selumetinib, which is the first selected therapy approved for patients who have neurofibromatosis type 1 and are suffering from symptomatic, inoperable plexiform neurofibromis. This approval of Koselugo forms part of our longstanding collaboration with colleagues at AstraZeneca, the group that first identified this important next signal transduction inhibitor. Outside of oncology, we also moved important programs forward in other therapeutic areas. Earlier in the quarter, we had the chance to present results from our Phase 3 VICTORIA study, done together with colleagues at Bayer, which showed that vericiguat, an investigational soluble guanylate cyclase agonist, provided benefit as judged by composite endpoints including heart failure hospitalization or cardiovascular death versus placebo, when administered as add on therapy to well treated patients with established heart failure with reduced ejection fraction who had suffered a worsening event.

Roger Perlmutter

executive
#7

This marks the initial investigation of this type within the population facing extremely elevated danger of additional heart-related issues. The findings appeared in the New England Journal of Medicine and were shared virtually at The American College of Cardiology Meeting only one month ago. Additionally, throughout the quarter we reported that in our Phase 3 program, gefapixant, our investigational P2X3 antagonist lowered the 24 hour cough frequency among patients suffering from longstanding chronic cough. Specifics regarding these outcomes will likewise be published and presented soon. Lastly, within the metabolic disease field, we have recently disclosed results from the Phase 3 VERTIS CV cardiovascular outcomes trial. In this trial run collaboratively by Merck and Pfizer, it compared giving STEGLATRO, an oral sodium-glucose cotransporter 2 or SGLT2 inhibitor, against placebo for treating patients who have type 2 diabetes along with established atherosclerotic vascular disease, and it hit its primary endpoint of non-inferiority regarding major adverse cardiovascular events. Those events were characterized as time to the first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke. The key secondary endpoints of superiority for STEGLATRO against placebo concerning time to the composite of CV death or hospitalization for heart failure, CV death by itself and the composite of renal death, dialysis/transplant or doubling of serum creatinine from baseline were not achieved. Though it wasn't a pre-specified hypothesis for statistical testing, a decrease in hospitalization for heart failure was seen with STEGLATRO. STEGLATRO's safety profile matched what had been reported in earlier studies. Full results from VERTIS CV are set to be shown on June 16th at the virtual American Diabetes Association’s 80th Scientific Session. I will now go over activities from the last quarter aimed at creating treatments that might influence the trajectory of the COVID-19 pandemic. As a top vaccine producer for over 100 years, it comes as no shock that we have started a wide-ranging development program for a SARS-CoV-2 vaccine. Let me frame these findings within the right context. Vaccine development is remarkably hard and typically demands many years of research. As others have pointed out over the last quarter century, in spite of massive attempts, just seven vaccines targeting previously unaddressed human pathogens have gained registration. Four among these seven came from Merck Research Laboratories. Thus we possess pertinent expertise in this domain. ERVEBO, our latest vaccine, which has been shown to offer protection from — with the Zaire strain of Ebola virus, was created swiftly and under emergency use authorization to assist in tackling outbreaks in West Africa. Still, it needed a multiyear development program and included constructing a factory that we're proud to say can generate 1 million doses of vaccine annually. The development and registration of ERVEBO demanded the work of hundreds of our employees along with an exceptional dedication from the World Health Organization and subsequently from healthcare workers in Guinea, Sierra Leone, the Democratic Republic of the Congo and numerous other jurisdictions. But the COVID-19 pandemic means we now have to develop an entirely novel vaccine in one-tenth of the time we spent on ERVEBO, and we need to prepare to produce it at a scale 1,000 times larger. We took on this task eagerly, yet also with modesty; our long experience tells us that bringing safe and effective vaccines into existence usually takes decades of work and funding. We remain aware of how essential it is to move quickly — truly, with urgency. Given how far we've come, I'll state that I feel hopeful a vaccine able to trigger a strong neutralizing immune response against SARS-CoV-2 can be created. Still, it's equally vital that we build a thorough grasp of this specific coronavirus, which would let us design, develop, and eventually produce a vaccine deployable across the world. To that end, we initially backed work aimed at characterizing effective immune responses following SARS-CoV-2 infection. As was announced yesterday, we've joined forces with researchers at the Institute for Systems Biology, Swedish hospital, and the Providence health system, all located in Seattle, together with Stanford University and many other parties, to gather cells and sera across several time points from people given a COVID-19 diagnosis. Findings from such analyses will be shared with investigators globally, and will put us in position to decode correlates of immunity against this coronavirus. Regarding the vaccines as such, we've been careful to choose established platforms that previously yielded vaccines with favorable characteristics. Naturally, given what I said earlier about how hard it is to succeed in vaccine development, I can't promise that any of these methods will turn out to work in the near term; even so, you may be certain that scientists in our labs and in those of our partners remain dedicated to this effort. We've likewise sought out internal resources capable of backing production of these prospective new vaccines at a suitable scale. And we're now talking with contract manufacturers who might help with what would undoubtedly be the hardest vaccine manufacturing endeavor ever attempted. Alongside our pursuit of vaccines, we're also examining possible antiviral medications that might be rolled out faster. Here as well, we've assessed compounds in our own labs and pinpointed programs at other labs that might deliver benefits. There isn't time for me to detail these programs. Rather, I want to note that the worldwide biopharmaceutical industry has shown great willingness to cooperate in tackling this problem. Inside MRL, we're striving to support as many of our colleagues as we can, through the active consortium run by the National Institutes of Health and through conversations with numerous companies, big and small, that have reached out seeking guidance and help with their own efforts. Let me finish by stressing that our mission at Merck is to turn breakthrough research into medicines and vaccines that enhance and prolong lives. At no point has this mission felt as essential as it does right now. I want to thank every one of my colleagues at Merck for their tireless efforts as we chase a way to ease the COVID-19 pandemic. With that, I'll hand the call back over to Peter.

Peter Dannenbaum

executive
#8

Thanks, Roger. Jerome, as you’re getting the queue ready, I’d like to give everyone a quick reminder. Today our opening remarks ran a little longer than usual. We’re ready to continue beyond 09:00. Even so, we ask that you keep yourself to one or two questions, which will let us include as many people asking as we can; so, thanks. Jerome, please go ahead and get the queue lined up.

Terence Flynn

analyst
#9

Perhaps a couple of things from my side. I'm just curious — I realize you touched on this somewhat — but when it comes to the landscape and how you think about deploying capital, I realize you've mentioned that there won't be any additional share buybacks. So could you share a bit more about what's primarily behind that? Is it that you're now seeing a growing number of M&A or BD possibilities in this landscape? And then the second thing, I was curious regarding the pharma guidance, and in particular, that updated guidance. Could you provide additional detail about how the impact will be timed? My assumption is that most of it will land in the second quarter; and then could you split that out by product, meaning how much came from KEYTRUDA as opposed to GARDASIL as opposed to others? Thank you.

Rob Davis

executive
#10

On perhaps the second question first, with the pharma guidance, most of it will land in the second quarter, and most of it is within the United States. And perhaps I'll hand it to Frank so he can give you a few of the finer points on the product specifics before I return to the first question.

Frank Clyburn

executive
#11

Right. So for Q2, we're expecting an effect on vaccines specifically. It's worth pointing out that our vaccine lineup is quite wide, covering everyone from babies through to the elderly. And given that well visits have dropped by roughly 70%, we expect that to have an effect on our vaccines as well. Then in the hospital specialty segment, BRIDION — like I said earlier — elective procedures are down around 70%. So yes, we see an impact there too. It's worth noting we have a major product, IMPLANON/NEXPLANON, that has to be given by a physician. We believe there will be an impact in the second quarter. Now regarding oncology, on the whole we think oncology is fairly resilient; new patient visits are falling by somewhere around 10% to 20%, depending on which indication you look at, and we expect a modest effect in the quarter when it comes to new patients, though we feel quite confident as we head into Q3 and Q4, not just for oncology but across the remainder of our portfolio. Rob?

Rob Davis

executive
#12

Appreciate that, Frank. Now, regarding what you asked about the buyback, let me make it clear — I mentioned this in my prepared comments, but it deserves repeating. Our choice to pause the repurchase program for the time being was made mainly because we wanted to be extremely careful. Our financial standing remains solid. And like we said, the reason was really to guarantee that we can keep making every investment we're aiming for in R&D and CapEx to fuel our growth going forward, plus in business development, which you brought up. So across each of those areas, we want to be certain we can put investment first. We'll keep monitoring it, and it's quite possible we bring back the share repurchase as we watch how things develop in the market.

Peter Dannenbaum

executive
#13

Thanks. Who's next?

Chris Schott

analyst
#14

To build on what was said regarding vaccines, could you elaborate a bit further on your expectations for how that segment will return to normal? It certainly sounds like second-quarter patterns will be weak; so ought we to anticipate a rebound during the third and fourth quarters once wellness visits resume, or does it look more like typical volumes, meaning we shouldn't count on much of a rebound, I suppose, particularly for that line? My other question is a broader one — we're obviously witnessing elevated jobless figures, and what does that mean in a wider sense for Merck's operations? Should we regard reduced pricing and an unfavorable payer mix as a drag on your operations when we look past these short-term COVID interruptions, or is that something manageable as we consider the business over a longer horizon? Many thanks.

Frank Clyburn

executive
#15

Hello, Chris, this is Frank. I appreciate the question. I'll address your second one first, concerning payer mix and its effect. Let me provide some detail on our U.S. mix. Roughly speaking, Chris, commercial accounts make up around one-third of our operations in terms of mix. Roughly 17% of our mix, and this is worth highlighting, comes from private-pay vaccines, given how large our vaccine portfolio is, as we've been discussing. Roughly fifty percent of our total payer mix involves government. Yet it's also worth highlighting that half of that figure, or roughly 26% to 27%, stems from KEYTRUDA, owing to Medicare Part B. So as we've said, with KEYTRUDA's continued expansion, we expect that share to rise in the future. Medicare Part D — Medicaid Part, rather — accounts for a modest share, roughly 7%. After that, a really tiny slice of our operations involves Medicaid. The remainder is largely miscellaneous, covering federal and certain other components of our payer mix; however, when you examine our portfolio, Medicaid's share is quite tiny. We're definitely watching jobless figures, and we'll need to keep tracking them going forward. In my view, it's premature to presume anything right now. That said, our guidance incorporates various scenarios in which joblessness might rise. For us especially, though, Medicaid accounts for only a minor slice of our operations. Turning to vaccines, to offer a bit more clarity, we anticipate that as you approach — or reach the latter part of the second quarter, moving into the third quarter, we anticipate that babies and small children who skipped their vaccinations amid COVID-19 will be given priority first. After that, we anticipate adult pneumococcal vaccines rebounding robustly as we move toward flu season. Following that, we anticipate teens and younger adults will likely return somewhat more gradually, Chris, once patients can interact with healthcare systems.

Peter Dannenbaum

executive
#16

Excellent. Could we take the following question, please?

Tim Anderson

analyst
#17

Yeah, thanks. I'm certain you've noticed that, up to now, Merck stands alone in cutting its outlook, yet we might be just halfway done. We've been seeing firms report; and I'm honestly attempting to figure out what, apart from product mix, might be behind that. Is it that you folks are operating your supply chain more tightly, or that you're less capable of managing the business from a work-from-home setting? Might it be that you're perhaps being more cautious, say, by halting share buybacks? At Merck, I believe there's been quite a solid cash position. You've got a deceleration in brands, yet I'd imagine you also have a deceleration in spending that you could locate as an offset, again echoing what other firms appear able to achieve in their guidance; so, I'm not sure whether there's anything further you can provide beyond your earlier comments, but it simply seems strange to me. My second question concerns KEYTRUDA, and a significant industry concern is data from Roche, a solid oncology firm, it's a randomized Phase 2, its first-line lung that's arriving here at ASCO most likely, and we understand they're advancing into Phase 3. And so I'm curious, how will this not become a persistent variable for American investors? Along those lines, if you could just bring us up to date on your own TIGIT program, which I realize is earlier.

Ken Frazier

executive
#18

I believe we'll begin with Rob, then hand it to Roger regarding TIGIT.

Rob Davis

executive
#19

Appreciate that, Tim. Now, when you examine the reason behind our guidance cut, and you take into account — once more — what our business looks like, I believe it's genuinely crucial that we drive this point home clearly: diminished access is precisely what stands behind the downward revision to guidance. That's because, as Frank noted, two-thirds of the products we sell get administered by physicians, which is likely a fairly unusual situation and is what's producing this effect. And like we mentioned, although we anticipate returning to normal levels by the time the fourth quarter arrives, since a sizable hit will land mostly during the second quarter and somewhat in the third, that Q2 damage mostly persists across the entire year, and that's genuinely what's fueling it. Another point worth flagging: the decline in our Human Health segment accounts for just slightly more than 50% of what's pushing our guidance lower. In fact, close to half of the total comes from foreign exchange movements, plus the effect we're absorbing in Animal Health; and when you break it down, the Animal Health hit is genuinely bigger than the one in the Human Health segment. So that too represents a bit of a distinguishing factor compared with certain competitors of ours. Then, when you trace how this flows down to the bottom line, what emerges is that across the full year, we're in fact reducing OpEx by more than the effect of the COVID-19 spend cuts alone. Part of that also stems from how currency moves through our operating expense line, though beyond that there's a modest amount of additional savings we had factored in. I'd say the reason we didn't push harder on OpEx is chiefly that we don't view this as something caused by demand, and we want to be positioned so that once the market stabilizes, we can bring our products back at full strength. So we intend to keep funding research and development — R&D will keep expanding — and we'll keep making targeted investments so we're ready to rebound strongly once the market settles; that's the reason we haven't cut OpEx any further. But nothing beyond our business mix, and the reality that access constraints are hurting our capacity to deliver what we initially projected for the year, should be read into this. Roger on TIGIT?

Roger Perlmutter

executive
#20

Okay, I'll address the KEYTRUDA combinations in broader terms. Truly, from the moment we started — from when I first got involved with the KEYTRUDA program in 2013 — we've been investigating a wide range of pairings with different agents. That is what naturally brought us to our alliance with AstraZeneca around Lynparza, and our alliance with Eisai around Lenvima, and it also drove us to build out an entire collection of internal programs that we're testing alongside KEYTRUDA across multiple clinical trials, such as TIGIT, plus many other biologicals that are quite far along in development. As I've said previously, some of these combinations have given us data that is genuinely rather striking. Above all, naturally, that applies to our Lenvima pairing, where we hold registration in endometrial cancer and have already shared results for the combination in renal cell carcinoma. But past that, with the biologicals too, we're pursuing effects that are genuinely meaningful and that will represent a substantial difference when it comes to efficacy, all while maintaining the highly favorable profile KEYTRUDA has already shown. So our progress is solid. We're eager to move some of these agents forward, provided these pan out. And naturally, we'll keep an eye on what others are doing. My sense is that we're positioned very well.

Peter Dannenbaum

executive
#21

Can we take the next question, please?

Mara Goldstein

analyst
#22

I'd like to dig a bit deeper into the currency topic, if that's alright. What I'm wondering is, when you consider how you arrived at these currency-related changes, could you offer additional detail regarding which portion stems from contracts and which portion reflects actual moves in exchange rates from one country to another? Also, would you be able to verify when the split off is scheduled, considering all the circumstances surrounding COVID?

Rob Davis

executive
#23

Regarding currency, when you examine what's behind the decrease, the whole thing stems from where we observed rates as of mid-April. Essentially, we adopted the exchange rates from mid-April and presumed they would remain in place through the entire year. Because of the reality that what you're witnessing is that against practically every currency, the dollar has gotten stronger owing to a rush back toward the dollar — as soon — as the reliable currency and as a protective step, that's creating an effect on us; it's affecting us throughout every one of our currencies; yet crucially, something else is occurring too — and we cannot hedge to the same extent we typically do since we're additionally experiencing a significant effect on emerging market currencies, where we currently don't hedge; therefore that is completely what's causing the $750 million decrease we referenced in our guidance. Now regarding your second question about when the spin out will occur. As Ken mentioned during his prepared remarks, our expectation remains that the spin out will be finished within the first half of 2021; that aligns with the guidance we provided last quarter.

Peter Dannenbaum

executive
#24

Great. Can we take the next question?

Navin Jacob

analyst
#25

This is Navin calling in from UBS. Roger, I'd like to ask you something regarding the COVID-19 vaccine program. It caught my attention when you brought up, or rather emphasized, that the decision was made to use platforms with a proven track record. I'm curious what you think about newer platforms, mRNA being one example — why might you be considering them, or why might you not be? And tied to that, I'd also appreciate hearing your perspective on neutralizing antibodies, whether as a treatment option or for prophylaxis. And following on from that, though distinct, I'm curious about your perspective on whether changes in the spike protein might drive selective pressure, and how you weigh considerations like that, or whether antibody-dependent enhancement could be shaping your views on established platforms as opposed to newer ones? Thanks a lot.

Roger Perlmutter

executive
#26

Okay, well, thank you. I appreciate the question very much. To start, we're open to every possible strategy that might help lessen the toll of the COVID-19 pandemic. We've talked with nearly every group pursuing this from different angles — whether that means passive immunization through antibodies, or other routes to active immunization that can reach clinics faster, such as nucleic acids and especially mRNA. And naturally, working with those kinds of researchers is something we've done collaboratively for many years. What we believe is that the job ahead calls for a shot capable of provoking a strong immune response — one that, in the best case, produces neutralizing antibodies after just one dose. Naturally, safety has to come first, since this is a product that in theory would be administered to a large share of people globally as a way of safeguarding them. Given our view that nearly everyone lacks immunity, each of these standards is a demanding one. So we're drawn back toward platforms with a track record of delivering such properties. That is exactly where our attention has gone. Looking ahead, my sense is that protecting humanity from SARS-CoV-2 will eventually require a range of vaccines, not just one. That is the perspective we have taken. When it comes to neutralizing antibodies given as passive vaccination, we have examined quite a few candidates. For the immediate future, that strategy could prove valuable for patients — possibly as a treatment — and also for people facing extremely elevated risk, whose age and comorbidities make them especially vulnerable. As a wide-scale way to shield the whole population, though, I suspect it will see less use, largely because of logistical challenges. That isn't to say we'd refuse to collaborate with other parties on advancing that, should it turn out to be what matters most in the short run. Last, to get things in the proper order, when it comes to mutation and selective pressure, we ought to keep in mind that although at present we aren't observing a great deal of diversity in SARS-CoV-2, once selective pressure gets applied to the virus — whether through an antiviral drug, and a few of those genuinely appear encouraging in these early days, or through a vaccine — it's possible that variants will show up, and those variants could turn out to matter. That's another item we're devoting a good deal of attention to.

Peter Dannenbaum

executive
#27

Thanks. Can we take the next question, please?

David Risinger

analyst
#28

Yeah, many thanks. There are a couple of things I'd like to ask Roger. Following up on what you said about COVID, would you be able to address the possibility of, first, injecting disinfectants, and second, applying UV rays within the body as a COVID cure? No, that was only a joke, my apologies. So, turning to something more serious, could you talk about which readouts for Merck's novel I/O agents we should be watching during 2020? And then secondly, could you talk about how confident you are in the profile of Merck's 15-valent pneumococcal conjugate vaccine, and about what you've disclosed regarding plans for filing in adults? Thanks.

Roger Perlmutter

executive
#29

Yes, David. Regarding novel immuno-oncology agents, I mean, some of this came up earlier when I answered a previous question, but we have a collection of them; naturally we're examining our own CTLA-4 molecule, and have been doing so for quite a while alongside KEYTRUDA. We're also examining LAG-3, TIGIT, and numerous others. Roughly 20 agents have been put through testing in the clinic, and every one of them is being evaluated as monotherapy and then afterward in combination with KEYTRUDA. Still, I want to stress that KEYTRUDA is genuinely rather exceptional; nothing we've encountered, naturally, has features resembling those of KEYTRUDA. If something did, the situation would look entirely different; that isn't surprising, since we along with many other investigators, including university-based ones and myself, spent decades searching for such things and never came across anything resembling KEYTRUDA. It's improbable that we'll simply stumble onto one at this point when nothing like it turned up previously. That said, it doesn't mean those things, when combined with KEYTRUDA, couldn't deliver benefit, and we're observing some early signals pointing to that possibility, and we'll be able to share considerably more on this over the next year; and the other question concerned how confident we are about our 15-valent molecule V114 for invasive pneumococcal disease. Our confidence in it is substantial. I believe our Phase 2 data have already been reported and everyone has had the opportunity to review them. Phase 3 data are going to reach us extremely soon. And the moment those data arrive, provided the Phase 3 results mirror what Phase 2 showed, which is definitely what we hope and expect, those — the top-line results will of course be made public, and at that stage we'll offer greater clarity regarding our filing plans. But what we expect is that filing might happen shortly after that. So we're genuinely very excited about this vaccine, given the significant new serotypes it contains and also the balance in immune response that our Phase 2 V114 studies demonstrated.

Peter Dannenbaum

executive
#30

Thanks. Let's take the next question.

Steve Scala

analyst
#31

Two things from me. You've made it clear that Q1 came in above expectations, yet the outlook for the whole year was cut. Roughly one-third of Q2 is behind us now, and April might turn out to be the worst point of the pandemic. Surely you're witnessing a significant hit across oncology, vaccines, hospital, and Animal Health. Does that seem like a fair assumption? Then, Roger, a lot of investors found the vericiguat and gefapixant data disappointing. From where you sit, what are they not seeing? Thanks.

Ken Frazier

executive
#32

Okay, Frank, you go first.

Frank Clyburn

executive
#33

Okay, Steve, I'll take that one first. So, responding to what you asked — yeah, Steve, like I said during my prepared remarks, when it comes to vaccines, the drop in patients and well visits is having an effect on us; we're also seeing a decline specifically in our hospital specialty business, BRIDION, tied to fewer elective surgeries, plus Women's Health. That's what we're observing in Q2, and it's the reason we revised our guidance. Still, we want to emphasize that, just as we're seeing in China, once we move past this stretch, we expect a gradual recovery in Q3. After that, by the time Q4 arrives, operations should be back to normal. And I'd like to keep stressing how confident we remain in the portfolio overall and in the demand trends we're seeing.

Rob Davis

executive
#34

Also, regarding the Animal Health side, I’d like to mention that. The circumstances there mirror what we’re facing in Human Health. At present, during this quarter, we’re already feeling the effects, and we anticipate that Q2 will account for the overwhelming share of the impact that produces the decrease for the entire year. Thus, it will certainly be at its worst during Q2, yet it will persist somewhat into Q3 and Q4, and be somewhat more extended than what we anticipate from the Human Health segment, resulting in a bigger negative effect on our Animal Health operation than the one it’s exerting on our Human Health operation.

Ken Frazier

executive
#35

Okay, Roger?

Roger Perlmutter

executive
#36

Yes, Steve, and thank you for asking that. Let me start with vericiguat and the VICTORIA study. The VICTORIA study looked at a group of patients who are usually left out of most trials — those whose condition has recently worsened. These individuals have heart failure with reduced ejection fraction and generally have been hospitalized because of some decline in their health. As a result, if you examine the published data, this is a very fragile group. What became clear, though, is that these patients were genuinely very sick, and their markers of heart failure and cardiac stress were far, far greater than what you would normally see among people with heart failure. That is exactly why the paper appeared in the New England Journal of Medicine, and why there was a plenary presentation at the American College of Cardiology covering these findings — because this is such a distinct group, and the treatment is administered on top of existing heart failure therapies while improving outcomes. So that is a fairly significant finding, and I believe there is considerable enthusiasm for it among the cardiovascular community and among physicians who manage heart failure. I think that is truly essential to appreciate. This represents quite a shift in the way we view these patients, and it is a vital population to treat. Then, turning to gefapixant — naturally, we have not yet presented the gefapixant data. We will get that opportunity. I think everyone ought to keep two points in mind. The first is that chronic cough is an incredibly frequent complaint among the general population. Physicians are therefore frequently asked to try to assist people whose lives are disrupted by chronic cough, and in our Phase 3 studies we had some participants who had complained of chronic cough, persistent chronic cough, for more — for decades. So this is a very substantial disruption to their lives. On the other hand, I do not want to minimize how hard it is to enter a totally new area, since there has been no — there has not been any drug approved for chronic cough. No study like this has existed before. This is an entirely novel space. It will require some time for this to advance and for people to grasp it.

Peter Dannenbaum

executive
#37

Excellent. Let's take the following question.

Louise Chen

analyst
#38

My initial inquiry concerns the TMB-High opportunity in this case. How large is that for Merck? Additionally, does off-label use of KEYTRUDA already occur within that group, and if it does, what is the extent? My second question then: could you give additional detail regarding the Taiho-Astex KRAS opportunity, and when might we begin seeing data from that pipeline asset? Thanks.

Ken Frazier

executive
#39

Regarding your first question about TMB-High. Roger, could you address TMB-High, and the second question as well?

Roger Perlmutter

executive
#40

All right. So, regarding TMB-High — the rationale behind our filing is a trial conducted across a range of tumor types, the KEYNOTE-158 study, where the responses seen so far leave something to be desired. So the aim was to investigate whether there was any way to show, in these tumor types, that KEYTRUDA could produce an effect in particular patients, and we examined a number of different markers that might be useful. What emerged for us was that a tumor mutational burden marker above 10 mutations per megabase correlated with a better overall response among some of these tumors, and that is the basis on which we have pursued registration, and we are currently in the middle of those conversations with the agency. So we will find out what happens. Honestly, I am not aware of any off-label usage, and we would not really have any way of knowing about that within that population; and as for our KRAS program, it is in fact a fairly wide-ranging effort examining both the GDP and GTP bound forms of KRAS and examining mutations past the cysteine mutation, the codon 12 mutation, the veiled cyst mutation that appears in a subset of patients, though naturally there are numerous other mutations, aspartic acid substitution, valiant substitution and so on. So we are casting a fairly wide net, but some time will pass before we get the chance to move the first of those compounds into the clinic.

Peter Dannenbaum

executive
#41

Thanks a lot. There are still quite a few people waiting to ask something. We'll wrap up at 9:15, though for the moment we'll continue. Let's take the following question.

Andrew Baum

analyst
#42

My first question is for Roger regarding TIGIT. You have obviously observed efficacy signals coming out of your trial work. Genentech has said it is observing robust efficacy signals among those with high PD-L1. So is the main factor preventing you from moving ahead with any Phase 3 study the question of whether TIGIT adds to or works synergistically with chemo among patients whose tumors express low levels of PD-L1, or is there a different obstacle standing in your way? And along those lines, how do you think about the commercial risk and reward of spending more time refining the patient population while possibly putting yourself at a disadvantage by handing Roche additional lead time, should that Phase 3 trial in first-line non-small cell lung cancer combined with chemo succeed? That is my first question. My second question goes very quickly to Frank. You have talked about the rather evident effect of people delaying visits to healthcare providers for pharmaceuticals that are administered by third parties. Could you share your thinking about the United States and the commercial effect tied to climbing insurance rates linked to unemployment? I understand that your exposure is much smaller than that of certain competitors, but I would like to hear your general perspective, though clearly it connects to items like Diovan as well, where, as you say, you do have commercial exposure. Thank you.

Ken Frazier

executive
#43

Great. Roger, TIGIT first, and after that we will hand things over to Frank.

Roger Perlmutter

executive
#44

Andrew, thanks for raising that. When it comes to TIGIT, perspectives are going to differ from one company to another. Ours remains pretty straightforward, and I wouldn't complicate it beyond what it is. What we're after is enough proof of a benefit from combining agents — enough that you can state without ambiguity that both components, meaning in our situation KEYTRUDA plus the anti-TIGIT antibody, are each pulling their weight, and the same logic applies to LAG-3, CTLA-4, or anything else in that space — such that you get at minimum an additive effect, and ideally something beyond that if it's achievable. So we need to be completely certain of that, completely certain we're targeting the correct patient populations, and naturally certain there's no worsening of KEYTRUDA's favorable adverse experience profile; it simply comes down to arriving at a conclusion on those points. It's possible we end up deciding that, you know, we don't believe it's good enough, and there could be all sorts of reasons behind that, or we could end up deciding that yes, this matters a great deal, so let's proceed. We have several programs where we're sort of examining exactly that, and we will come across some data that's intriguing, yet we simply lack sufficient data at this point to feel at ease about it. Someone else might review those same results and conclude that immediate action is needed. In that respect, we're doing what we believe is correct.

Ken Frazier

executive
#45

Great, Frank?

Frank Clyburn

executive
#46

And Andrew, obviously all of us share concern about what's happening in the U.S. when it comes to unemployment climbing. Like I said before, in our case, we may see a potential move away from our commercial business toward segments with bigger discounts, such as Medicaid. Still, to say it once more, Medicaid currently makes up only a very small piece of what we do, and looking ahead, Medicare—especially Part B Medicare—plays a larger role in our business and payer mix.

Peter Dannenbaum

executive
#47

Excellent. Let's take the next one, please.

Seamus Fernandez

analyst
#48

Excellent, I really appreciate the question. So, only a few items here. Could you folks weigh in — I realize we already touched on the Medicaid piece, though 340B expansion might pose a serious risk to the whole industry. I'm simply attempting to gain a clearer picture of how much 340B exposure Merck faces right now, given that it's a hospital-based program that could later move to pricing tied to Medicaid; so I'd really like a clearer picture of your views regarding that exposure. Then, turning to Roger, could you help us grasp what makes Lenvima distinctive or special, such that Merck is chasing such a wide-ranging push when others holding comparable TKIs definitely are not, and this is where I'd really like you to address the differentiation, as they haven't gone after that. And I think this stands out especially given how comparatively short Lenvima's patent life is. Many thanks.

Ken Frazier

executive
#49

Frank, after that Roger.

Frank Clyburn

executive
#50

Yeah, Seamus, so regarding 340B — most of that exposure comes from drugs such as JANUVIA and KEYTRUDA as well; with KEYTRUDA, roughly one-third sits in the 340B segment right now; that share has been ticking up modestly year over year, and as I said, we'll need to watch how matters keep developing in terms of what's going on in the landscape, and it's clearly something we're keeping a close eye on.

Ken Frazier

executive
#51

OK, Roger, about Lenvima?

Roger Perlmutter

executive
#52

Sure. Seamus, we really let the data guide us here. Early on, the monotherapy results our Eisai colleagues had generated made us hopeful about Lenvima, and we believed there was a possibility it might work well alongside KEYTRUDA. We ran some trials of that kind together with them, and afterward we entered into our agreement; once that agreement was signed, we decided to conduct a signal detection study spanning a wide range of tumors. Having done so, we've observed numerous signals that are genuinely quite intriguing. Naturally, those weren't the sole multi-kinase inhibitor combinations we tested, yet we've found striking signals when paired with KEYTRUDA. And as everyone knows, no two multi-kinase inhibitors are alike. Every agent targets a distinct spectrum of molecules, and their impacts differ; consequently it's rather difficult to explain why this holds true and whether it stems from VEGF receptor antagonism alongside FGF receptor or something else. What can be stated, though, is that none of them are the same, and the outcomes we've achieved using Lenvima are extremely encouraging. So clearly we're very enthusiastic — starting with endometrial, then other tumors, the renal data we shared, and plenty more beyond those. So that program is moving ahead.

Peter Dannenbaum

executive
#53

That’s great. Thanks to everyone for your questions, and sorry to anyone we weren’t able to reach. I’ll now hand things over to Ken for some closing comments.

Ken Frazier

executive
#54

I appreciate everyone being here with us today. The goal we hold of preserving and bettering lives is going to keep steering the Company over the days and months ahead while the coronavirus pandemic continues. Merck is fully dedicated to doing all it can so that our medicines and vaccines get to patients worldwide, and we anticipate adding to the worldwide fight against this pandemic right now as well as getting ready for whatever potential crisis comes next. Demand underneath for what we sell stays robust, and the basics of our business stay quite solid. Over the short term, we — let me say again, our portfolio is not the same as others, so our short-term guidance factors in what is genuinely occurring in the world beyond us, trying to be realistic regarding physicians and whether they can reach patients. Yet when everything is considered, we hold the view that the fundamentals beneath our business are quite solid as we move forward, and we are eager to give updates about the business as we keep finding our way through these difficult times. Until that point, we hope you and your families stay safe and well. Thank you.

Peter Dannenbaum

executive
#55

Thank you.

Operator

operator
#56

Appreciation to our presenters, and to everyone on the line, for being part of Merck & Company's conference call covering first quarter sales and earnings. That brings this conference to a close. Many thanks to all of you for participating. You are welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.